{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:21:36Z","timestamp":1789298496819,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The inability of biologics to pass the plasma membrane prevents their development as therapeutics for intracellular targets. To address the lack of methods for cytosolic protein delivery, we used the type III secretion system (T3SS) of\n                      <jats:italic>Y.\u00a0enterocolitica<\/jats:italic>\n                      , which naturally injects bacterial proteins into eukaryotic host cells, to deliver monobody proteins into cancer cells. Monobodies are small synthetic binding proteins that can inhibit oncogene signaling in cancer cells with high selectivity upon intracellular expression. Here, we engineered monobodies targeting the BCR::ABL1 tyrosine kinase for efficient delivery by the T3SS, quantified cytosolic delivery and target engagement in cancer cells and monitored inhibition of BCR::ABL1 signaling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro assays were performed to characterize destabilized monobodies (thermal shift assay and isothermal titration calorimetry) and to assess their secretion by the T3SS. Immunoblot assays were used to study the translocation of monobodies into different cell lines and to determine the intracellular concentration after translocation. Split-Nanoluc assays were performed to understand translocation and degradation kinetics and to evaluate target engagement after translocation. Phospho flow cytometry and apoptosis assays were performed to assess the functional effects of monobody translocation into BCR:ABL1-expressing leukemia cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>To enable efficient translocation of the stable monobody proteins by the T3SS, we engineered destabilized mutant monobodies that retained high affinity target binding and were efficiently injected into different cell lines. After injection, the cytosolic monobody concentrations reached mid-micromolar concentrations considerably exceeding their binding affinity. We found that injected monobodies targeting the BCR::ABL1 tyrosine kinase selectively engaged their target in the cytosol. The translocation resulted in inhibition of oncogenic signaling and specifically induced apoptosis in BCR::ABL1-dependent cells, consistent with the phenotype when the same monobody was intracellularly expressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Hence, we establish the T3SS of\n                      <jats:italic>Y.\u00a0enterocolitica<\/jats:italic>\n                      as a highly efficient protein translocation method for monobody delivery, enabling the selective targeting of different oncogenic signaling pathways and providing a foundation for future therapeutic application against intracellular targets.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-024-01874-6","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:02:07Z","timestamp":1729083727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling"],"prefix":"10.1186","volume":"22","author":[{"given":"Chiara","family":"Lebon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Diepold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hantschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"1874_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1874_CR2","doi-asserted-by":"publisher","first-page":"106552","DOI":"10.1016\/j.phrs.2022.106552","volume":"187","author":"R Roskoski","year":"2023","unstructured":"Roskoski R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552. https:\/\/doi.org\/10.1016\/j.phrs.2022.106552.","journal-title":"Pharmacol Res"},{"key":"1874_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278\u201387. https:\/\/doi.org\/10.1038\/nrc3236.","journal-title":"Nat Rev Cancer"},{"key":"1874_CR4","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185:2789\u2013805. https:\/\/doi.org\/10.1016\/j.cell.2022.05.029.","journal-title":"Cell"},{"key":"1874_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-024-00996-w","volume":"31","author":"M Kumar","year":"2024","unstructured":"Kumar M, Jalota A, Sahu SK, Haque S. Therapeutic antibodies for the prevention and treatment of cancer. J Biomed Sci. 2024;31:6. https:\/\/doi.org\/10.1186\/s12929-024-00996-w.","journal-title":"J Biomed Sci"},{"key":"1874_CR6","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","volume":"54","author":"HY Min","year":"2022","unstructured":"Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54:1670\u201394. https:\/\/doi.org\/10.1038\/s12276-022-00864-3.","journal-title":"Exp Mol Med"},{"key":"1874_CR7","doi-asserted-by":"publisher","first-page":"w14545","DOI":"10.4414\/smw.2017.14545","volume":"147","author":"O Hantschel","year":"2017","unstructured":"Hantschel O. Monobodies as possible next-generation protein therapeutics - a perspective. Swiss Med Wkly. 2017;147:w14545. https:\/\/doi.org\/10.4414\/smw.2017.14545.","journal-title":"Swiss Med Wkly"},{"key":"1874_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1021\/cb500886n","volume":"10","author":"O Hantschel","year":"2015","unstructured":"Hantschel O. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors. ACS Chem Biol. 2015;10:234\u201345. https:\/\/doi.org\/10.1021\/cb500886n.","journal-title":"ACS Chem Biol"},{"key":"1874_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583\u201392. https:\/\/doi.org\/10.1038\/nrc1893.","journal-title":"Nat Rev Cancer"},{"key":"1874_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","volume":"60","author":"M Gebauer","year":"2020","unstructured":"Gebauer M, Skerra A. Engineered protein scaffolds as next-generation therapeutics. Annu Rev Pharmacol Toxicol. 2020;60:391\u2013415. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010818-021118.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1874_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1134\/S0006297923090043","volume":"88","author":"TI David","year":"2023","unstructured":"David TI, Pestov NB, Korneenko TV, Barlev NA. Non-immunoglobulin synthetic binding proteins for oncology. Biochem (Moscow). 2023;88:1232\u201347. https:\/\/doi.org\/10.1134\/S0006297923090043.","journal-title":"Biochem (Moscow)"},{"key":"1874_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.sbi.2020.01.015","volume":"60","author":"O Hantschel","year":"2020","unstructured":"Hantschel O, Biancalana M, Koide S. Monobodies as enabling tools for structural and mechanistic biology. Curr Opin Struct Biol. 2020;60:167\u201374. https:\/\/doi.org\/10.1016\/j.sbi.2020.01.015.","journal-title":"Curr Opin Struct Biol"},{"key":"1874_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin S, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Therapy. 2022;7:39. https:\/\/doi.org\/10.1038\/s41392-021-00868-x.","journal-title":"Signal Transduct Target Therapy"},{"key":"1874_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pro.3148","volume":"26","author":"F Sha","year":"2017","unstructured":"Sha F, Salzman G, Gupta A, Koide S. Monobodies and other synthetic binding proteins for expanding protein science. Protein Sci. 2017;26:910\u201324. https:\/\/doi.org\/10.1002\/pro.3148.","journal-title":"Protein Sci"},{"key":"1874_CR15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1039\/D2CB00094F","volume":"3","author":"R Luo","year":"2022","unstructured":"Luo R, Liu H, Cheng Z. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy. RSC Chem Biology. 2022;3:830\u201347. https:\/\/doi.org\/10.1039\/D2CB00094F.","journal-title":"RSC Chem Biology"},{"key":"1874_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1006\/jmbi.1998.2238","volume":"284","author":"A Koide","year":"1998","unstructured":"Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol. 1998;284:1141\u201351. https:\/\/doi.org\/10.1006\/jmbi.1998.2238. S0022-2836(98)92238-0 [pii].","journal-title":"J Mol Biol"},{"key":"1874_CR17","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1074\/jbc.M115.707901","volume":"291","author":"J Wojcik","year":"2016","unstructured":"Wojcik J, et al. Allosteric inhibition of bcr-abl kinase by High Affinity Monobody inhibitors irected to the src homology 2 (SH2)-Kinase interface. J Biol Chem. 2016;291:8836\u201347. https:\/\/doi.org\/10.1074\/jbc.M115.707901.","journal-title":"J Biol Chem"},{"key":"1874_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nsmb.1793","volume":"17","author":"J Wojcik","year":"2010","unstructured":"Wojcik J, et al. A potent and highly specific FN3 monobody inhibitor of the abl SH2 domain. Nat Struct Mol Biol. 2010;17:519\u201327. https:\/\/doi.org\/10.1038\/nsmb.1793.","journal-title":"Nat Struct Mol Biol"},{"key":"1874_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cell.2011.08.046","volume":"147","author":"F Grebien","year":"2011","unstructured":"Grebien F, et al. Targeting the SH2-Kinase interface in Bcr-Abl nhibits Leukemogenesis. Cell. 2011;147:306\u201319. https:\/\/doi.org\/10.1016\/j.cell.2011.08.046.","journal-title":"Cell"},{"key":"1874_CR20","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jmb.2017.03.023","volume":"429","author":"T Kukenshoner","year":"2017","unstructured":"Kukenshoner T, et al. Selective targeting of SH2 domain-phosphotyrosine interactions of src family tyrosine kinases with Monobodies. J Mol Biol. 2017;429:1364\u201380. https:\/\/doi.org\/10.1016\/j.jmb.2017.03.023.","journal-title":"J Mol Biol"},{"key":"1874_CR21","doi-asserted-by":"publisher","first-page":"168010","DOI":"10.1016\/j.jmb.2023.168010","volume":"435","author":"F Sha","year":"2023","unstructured":"Sha F, et al. Monobody inhibitor selective to the phosphatase domain of SHP2 and its Use as a probe for quantifying SHP2 allosteric regulation. J Mol Biol. 2023;435:168010. https:\/\/doi.org\/10.1016\/j.jmb.2023.168010.","journal-title":"J Mol Biol"},{"key":"1874_CR22","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1038\/s41467-020-17920-z","volume":"11","author":"G La Sala","year":"2020","unstructured":"La Sala G, et al. Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains. Nat Commun. 2020;11:4115. https:\/\/doi.org\/10.1038\/s41467-020-17920-z.","journal-title":"Nat Commun"},{"key":"1874_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nchembio.2231","volume":"13","author":"R Spencer-Smith","year":"2017","unstructured":"Spencer-Smith R, et al. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol. 2017;13:62\u20138. https:\/\/doi.org\/10.1038\/nchembio.2231.","journal-title":"Nat Chem Biol"},{"key":"1874_CR24","doi-asserted-by":"publisher","first-page":"e2204481119","DOI":"10.1073\/pnas.2204481119","volume":"119","author":"L Wallon","year":"2022","unstructured":"Wallon L, et al. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the switch I\/II pocket. Proc Natl Acad Sci U S A. 2022;119:e2204481119. https:\/\/doi.org\/10.1073\/pnas.2204481119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1874_CR25","doi-asserted-by":"publisher","first-page":"e2302485120","DOI":"10.1073\/pnas.2302485120","volume":"120","author":"P Akkapeddi","year":"2023","unstructured":"Akkapeddi P, et al. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proc Natl Acad Sci U S A. 2023;120:e2302485120. https:\/\/doi.org\/10.1073\/pnas.2302485120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1874_CR26","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1039\/d1md00188d","volume":"12","author":"P Akkapeddi","year":"2021","unstructured":"Akkapeddi P, Teng KW, Koide S. Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Med Chem. 2021;12:1839\u201353. https:\/\/doi.org\/10.1039\/d1md00188d.","journal-title":"RSC Med Chem"},{"key":"1874_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fphar.2024.1393112","volume":"15","author":"AV Dinh-Fricke","year":"2024","unstructured":"Dinh-Fricke AV, Hantschel O. Improving the pharmacokinetics, biodistribution and plasma stability of monobodies. Front Pharmacol. 2024;15:15. https:\/\/doi.org\/10.3389\/fphar.2024.1393112.","journal-title":"Front Pharmacol."},{"key":"1874_CR28","doi-asserted-by":"publisher","unstructured":"Porello I, Cellesi F. Intracellular delivery of therapeutic proteins. New advancements and future directions. Front Bioeng Biotechnol. 2023;11.https:\/\/doi.org\/10.3389\/fbioe.2023.1211798","DOI":"10.3389\/fbioe.2023.1211798"},{"key":"1874_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20:101\u201324. https:\/\/doi.org\/10.1038\/s41573-020-0090-8.","journal-title":"Nat Rev Drug Discovery"},{"key":"1874_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/pharmaceutics13020155","volume":"13","author":"A Yau","year":"2021","unstructured":"Yau A, Lee J, Chen Y. Nanomaterials for protein delivery in Anticancer Applications. Pharmaceutics. 2021;13:13. https:\/\/doi.org\/10.3390\/pharmaceutics13020155.","journal-title":"Pharmaceutics."},{"key":"1874_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, et al. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56:836\u201349. https:\/\/doi.org\/10.1038\/s12276-024-01201-6.","journal-title":"Exp Mol Med"},{"key":"1874_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.chembiol.2017.06.014","volume":"24","author":"VJ Bruce","year":"2017","unstructured":"Bruce VJ, McNaughton BR. Inside job: methods for delivering proteins to the Interior of mammalian cells. Cell Chem Biology. 2017;24:924\u201334. https:\/\/doi.org\/10.1016\/j.chembiol.2017.06.014.","journal-title":"Cell Chem Biology"},{"key":"1874_CR33","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1021\/acs.bioconjchem.9b00112","volume":"30","author":"K Deprey","year":"2019","unstructured":"Deprey K, Becker L, Kritzer J, Pl\u00fcckthun A. Trapped! a critical evaluation of methods for measuring total cellular uptake versus cytosolic localization. Bioconjug Chem. 2019;30:1006\u201327. https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00112.","journal-title":"Bioconjug Chem"},{"key":"1874_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","volume":"16","author":"K Kardani","year":"2019","unstructured":"Kardani K, Milani A, Bolhassani A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin Drug Deliv. 2019;16:1227\u201358. https:\/\/doi.org\/10.1080\/17425247.2019.1676720.","journal-title":"Expert Opin Drug Deliv"},{"key":"1874_CR35","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.33549\/physiolres.933975","volume":"67","author":"E B\u00f6hmov\u00e1","year":"2018","unstructured":"B\u00f6hmov\u00e1 E, et al. Cell-penetrating peptides: a useful tool for the delivery of various cargoes into cells. Physiol Res. 2018;67:S267\u201379. https:\/\/doi.org\/10.33549\/physiolres.933975.","journal-title":"Physiol Res"},{"key":"1874_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201402290","author":"X Liao","year":"2014","unstructured":"Liao X, Rabideau AE, Pentelute BL. Delivery of antibody mimics into mammalian cells via Anthrax Toxin Protective Antigen. ChemBioChem. 2014. https:\/\/doi.org\/10.1002\/cbic.201402290.","journal-title":"ChemBioChem"},{"key":"1874_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acschembio.9b00113","volume":"14","author":"NE Schmit","year":"2019","unstructured":"Schmit NE, Neopane K, Hantschel O. Targeted protein degradation through cytosolic delivery of Monobody Binders using bacterial toxins. ACS Chem Biol. 2019;14:916\u201324. https:\/\/doi.org\/10.1021\/acschembio.9b00113.","journal-title":"ACS Chem Biol"},{"key":"1874_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/pep2.24168","volume":"112","author":"F Nadal-Buf\u00ed","year":"2020","unstructured":"Nadal-Buf\u00ed F, Henriques ST. How to overcome endosomal entrapment of cell-penetrating peptides to release the therapeutic potential of peptides? Pept Sci. 2020;112: e24168. https:\/\/doi.org\/10.1002\/pep2.24168.","journal-title":"Pept Sci"},{"key":"1874_CR39","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1038\/s41467-021-25448-z","volume":"12","author":"S Yu","year":"2021","unstructured":"Yu S, et al. Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. Nat Commun. 2021;12:5131. https:\/\/doi.org\/10.1038\/s41467-021-25448-z.","journal-title":"Nat Commun"},{"key":"1874_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108103","volume":"63","author":"E Volt\u00e0-Dur\u00e1n","year":"2023","unstructured":"Volt\u00e0-Dur\u00e1n E, et al. Endosomal escape for cell-targeted proteins. Going out after going in. Biotechnol Adv. 2023;63: 108103. https:\/\/doi.org\/10.1016\/j.biotechadv.2023.108103.","journal-title":"Biotechnol Adv"},{"key":"1874_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/femsle\/fny201","volume":"365","author":"S Wagner","year":"2018","unstructured":"Wagner S, et al. Bacterial type III secretion systems: a complex device for the delivery of bacterial effector proteins into eukaryotic host cells. FEMS Microbiol Lett. 2018;365:365. https:\/\/doi.org\/10.1093\/femsle\/fny201.","journal-title":"FEMS Microbiol Lett."},{"key":"1874_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chom.2023.03.007","volume":"31","author":"JP Lynch","year":"2023","unstructured":"Lynch JP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe. 2023;31:634\u201349. https:\/\/doi.org\/10.1016\/j.chom.2023.03.007.","journal-title":"Cell Host Microbe"},{"key":"1874_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s42003-020-1072-4","volume":"3","author":"A Chabloz","year":"2020","unstructured":"Chabloz A, et al. Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. Commun Biol. 2020;3:342. https:\/\/doi.org\/10.1038\/s42003-020-1072-4.","journal-title":"Commun Biol"},{"key":"1874_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.biotechadv.2018.01.016","volume":"36","author":"F Bai","year":"2018","unstructured":"Bai F, Li Z, Umezawa A, Terada N, Jin S. Bacterial type III secretion system as a protein delivery tool for a broad range of biomedical applications. Biotechnol Adv. 2018;36:482\u201393. https:\/\/doi.org\/10.1016\/j.biotechadv.2018.01.016.","journal-title":"Biotechnol Adv"},{"key":"1874_CR45","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1128\/jb.173.5.1677-1685.1991","volume":"173","author":"T Michiels","year":"1991","unstructured":"Michiels T, Cornelis GR. Secretion of hybrid proteins by the Yersinia Yop export system. J Bacteriol. 1991;173:1677\u201385. https:\/\/doi.org\/10.1128\/jb.173.5.1677-1685.1991.","journal-title":"J Bacteriol"},{"key":"1874_CR46","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1083\/jcb.201502074","volume":"211","author":"SJ Ittig","year":"2015","unstructured":"Ittig SJ, et al. A bacterial type III secretion-based protein delivery tool for broad applications in cell biology. J Cell Biol. 2015;211:913\u201331. https:\/\/doi.org\/10.1083\/jcb.201502074.","journal-title":"J Cell Biol"},{"key":"1874_CR47","doi-asserted-by":"publisher","first-page":"e15227","DOI":"10.1371\/journal.pone.0015227","volume":"5","author":"A Blanco-Toribio","year":"2010","unstructured":"Blanco-Toribio A, Muyldermans S, Frankel G, Fern\u00e1ndez L. Direct injection of functional single-domain antibodies from E. Coli into human cells. PLoS ONE. 2010;5:e15227. https:\/\/doi.org\/10.1371\/journal.pone.0015227.","journal-title":"PLoS ONE"},{"key":"1874_CR48","doi-asserted-by":"publisher","first-page":"12548","DOI":"10.1073\/pnas.0503407102","volume":"102","author":"MC Schlumberger","year":"2005","unstructured":"Schlumberger MC, et al. Real-time imaging of type III secretion: Salmonella SipA injection into host cells. Proc Natl Acad Sci U S A. 2005;102:12548\u201353. https:\/\/doi.org\/10.1073\/pnas.0503407102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1874_CR49","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nmeth804","volume":"2","author":"J Enninga","year":"2005","unstructured":"Enninga J, Mounier J, Sansonetti P, Van Tran G. Secretion of type III effectors into host cells in real time. Nat Methods. 2005;2:959\u201365. https:\/\/doi.org\/10.1038\/nmeth804.","journal-title":"Nat Methods"},{"key":"1874_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.chom.2007.11.007","volume":"3","author":"E Mills","year":"2008","unstructured":"Mills E, Baruch K, Charpentier X, Kobi S, Rosenshine I. Real-time analysis of effector translocation by the type III secretion system of enteropathogenic Escherichia coli. Cell Host Microbe. 2008;3:104\u201313. https:\/\/doi.org\/10.1016\/j.chom.2007.11.007.","journal-title":"Cell Host Microbe"},{"key":"1874_CR51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1046\/j.1365-2958.1998.01128.x","volume":"30","author":"CA Jacobi","year":"1998","unstructured":"Jacobi CA, et al. In vitro and in vivo expression studies of yopE from Yersinia enterocolitica using the gfp reporter gene. Mol Microbiol. 1998;30:865\u201382. https:\/\/doi.org\/10.1046\/j.1365-2958.1998.01128.x.","journal-title":"Mol Microbiol"},{"key":"1874_CR52","doi-asserted-by":"publisher","unstructured":"G\u00f6ser V, Kommnick C, Liss V, Hensel M. Self-labeling enzyme tags for analyses of translocation of type III Secretion System Effector proteins. mBio. 2019;10. https:\/\/doi.org\/10.1128\/mBio.00769-19.","DOI":"10.1128\/mBio.00769-19"},{"key":"1874_CR53","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1046\/j.1365-2958.2002.03241.x","volume":"46","author":"MF Feldman","year":"2002","unstructured":"Feldman MF, M\u00fcller S, W\u00fcest E, Cornelis GR. SycE allows secretion of YopE\u2013DHFR hybrids by the Yersinia enterocolitica type III ysc system. Mol Microbiol. 2002;46:1183\u201397. https:\/\/doi.org\/10.1046\/j.1365-2958.2002.03241.x.","journal-title":"Mol Microbiol"},{"key":"1874_CR54","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00792","volume":"2","author":"M Kudryashev","year":"2013","unstructured":"Kudryashev M, et al. In situ structural analysis of the Yersinia enterocolitica injectisome. Elife. 2013;2: e00792. https:\/\/doi.org\/10.7554\/eLife.00792.","journal-title":"Elife"},{"key":"1874_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41564-023-01545-1","volume":"9","author":"S Wimmi","year":"2024","unstructured":"Wimmi S, et al. Cytosolic sorting platform complexes shuttle type III secretion system effectors to the injectisome in Yersinia enterocolitica. Nat Microbiol. 2024;9:185\u201399. https:\/\/doi.org\/10.1038\/s41564-023-01545-1.","journal-title":"Nat Microbiol"},{"key":"1874_CR56","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1093\/infdis\/jiad077","volume":"228","author":"AA Ordonez","year":"2023","unstructured":"Ordonez AA, et al. Imaging tumor-targeting Bacteria using 18F-Fluorodeoxysorbitol positron emission tomography. J Infect Dis. 2023;228:S291\u2013296. https:\/\/doi.org\/10.1093\/infdis\/jiad077.","journal-title":"J Infect Dis"},{"key":"1874_CR57","unstructured":"Ittig S, Amstutz M, Kasper C. Bacteria-based protein delivery (patent no. WO2017085235A1). World Intellectual Property Organization; 2017.\u00a0https:\/\/data.epo.org\/publication-server\/rest\/v1.2\/patents\/EP3377634NWB1\/document.html."},{"key":"1874_CR58","unstructured":"Ittig S, Kasper C, Saupe F, Amstutz M, Duval M. Pharmaceutical combinations for treating cancer (patent no. WO2022200493A1). World Intellectual Property Organization; 2022.\u00a0https:\/\/patentimages.storage.googleapis.com\/f9\/04\/00\/233b62a6763179\/WO2017085235A1.pdf."},{"key":"1874_CR59","unstructured":"National Library of medicine (U.S) (2022, April - ). An Open-label, Phase I\/II Study of T3P-Y058-739, a Genetically-modified Strain of the Bacterium Yersinia Enterocolitica, in Patients With Advanced Solid Tumours. Identifier NCT05120596. https:\/\/clinicaltrials.gov\/study\/NCT05120596."},{"key":"1874_CR60","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"1874_CR61","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247:824\u201330.","journal-title":"Science"},{"key":"1874_CR62","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1073\/pnas.0700149104","volume":"104","author":"A Koide","year":"2007","unstructured":"Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A. 2007;104:6632\u20137. https:\/\/doi.org\/10.1073\/pnas.0700149104. 0700149104 [pii].","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1874_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/bj2140465","volume":"214","author":"D Watkins","year":"1983","unstructured":"Watkins D, Cooper BA. A critical intracellular concentration of fully reduced non-methylated folate polyglutamates prevents macrocytosis and diminished growth rate of human cell line K562 in culture. Biochem J. 1983;214:465\u201370. https:\/\/doi.org\/10.1042\/bj2140465.","journal-title":"Biochem J"},{"key":"1874_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019566118","volume":"118","author":"MA LeBlanc","year":"2021","unstructured":"LeBlanc MA, Fink MR, Perkins TT, Sousa MC. Type III secretion system effector proteins are mechanically labile. Proc Natl Acad Sci U S A. 2021;118: 118. https:\/\/doi.org\/10.1073\/pnas.2019566118.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1874_CR65","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nsmb.2722","volume":"21","author":"J Radics","year":"2014","unstructured":"Radics J, K\u00f6nigsmaier L, Marlovits TC. Structure of a pathogenic type 3 secretion system in action. Nat Struct Mol Biol. 2014;21:82\u20137. https:\/\/doi.org\/10.1038\/nsmb.2722.","journal-title":"Nat Struct Mol Biol"},{"key":"1874_CR66","doi-asserted-by":"publisher","first-page":"10326","DOI":"10.1021\/bi010916y","volume":"40","author":"A Koide","year":"2001","unstructured":"Koide A, Jordan MR, Horner SR, Batori V, Koide S. Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. Biochemistry. 2001;40:10326\u201333. https:\/\/doi.org\/10.1021\/bi010916y.","journal-title":"Biochemistry"},{"key":"1874_CR67","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/cb3002478","volume":"7","author":"MP Hall","year":"2012","unstructured":"Hall MP, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol. 2012;7:1848\u201357. https:\/\/doi.org\/10.1021\/cb3002478.","journal-title":"ACS Chem Biol"},{"key":"1874_CR68","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/mmi.14490","volume":"113","author":"S Westerhausen","year":"2020","unstructured":"Westerhausen S, et al. A NanoLuc luciferase-based assay enabling the real-time analysis of protein secretion and injection by bacterial type III secretion systems. Mol Microbiol. 2020;113:1240\u201354. https:\/\/doi.org\/10.1111\/mmi.14490.","journal-title":"Mol Microbiol"},{"key":"1874_CR69","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41467-020-16169-w","volume":"11","author":"F Lindner","year":"2020","unstructured":"Lindner F, Milne-Davies B, Langenfeld K, Stiewe T, Diepold A. LITESEC-T3SS - light-controlled protein delivery into eukaryotic cells with high spatial and temporal resolution. Nat Commun. 2020;11:2381. https:\/\/doi.org\/10.1038\/s41467-020-16169-w.","journal-title":"Nat Commun"},{"key":"1874_CR70","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acschembio.5b00753","volume":"11","author":"AS Dixon","year":"2016","unstructured":"Dixon AS, et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol. 2016;11:400\u20138. https:\/\/doi.org\/10.1021\/acschembio.5b00753.","journal-title":"ACS Chem Biol"},{"key":"1874_CR71","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","volume":"107","author":"D Ye","year":"2006","unstructured":"Ye D, Wolff N, Li L, Zhang S, Ilaria RL. Jr. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006;107:4917\u201325.","journal-title":"Blood"},{"key":"1874_CR72","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jmb.2011.12.019","volume":"415","author":"A Koide","year":"2012","unstructured":"Koide A, Wojcik J, Gilbreth RN, Hoey RJ, Koide S. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol. 2012;415:393\u2013405. https:\/\/doi.org\/10.1016\/j.jmb.2011.12.019.","journal-title":"J Mol Biol"},{"key":"1874_CR73","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1021\/acs.molpharmaceut.5b00233","volume":"12","author":"A Auger","year":"2015","unstructured":"Auger A, et al. Efficient delivery of structurally diverse protein Cargo into mammalian cells by a bacterial toxin. Mol Pharm. 2015;12:2962\u201371. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00233.","journal-title":"Mol Pharm"},{"key":"1874_CR74","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1166\/jnn.2014.9082","volume":"14","author":"HK Shete","year":"2014","unstructured":"Shete HK, Prabhu RH, Patravale VB. Endosomal escape: a bottleneck in intracellular delivery. J Nanosci Nanotechnol. 2014;14:460\u201374. https:\/\/doi.org\/10.1166\/jnn.2014.9082.","journal-title":"J Nanosci Nanotechnol"},{"key":"1874_CR75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1021\/sb500252a","volume":"4","author":"C Pi\u00f1ero-Lambea","year":"2015","unstructured":"Pi\u00f1ero-Lambea C, et al. Programming controlled adhesion of E. Coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth Biol. 2015;4:463\u201373. https:\/\/doi.org\/10.1021\/sb500252a.","journal-title":"ACS Synth Biol"},{"key":"1874_CR76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/femsre\/fuaa050","volume":"45","author":"MK Singh","year":"2020","unstructured":"Singh MK, Kenney LJ. Super-resolution imaging of bacterial pathogens and visualization of their secreted effectors. FEMS Microbiol Rev. 2020;45:45. https:\/\/doi.org\/10.1093\/femsre\/fuaa050.","journal-title":"FEMS Microbiol Rev."},{"key":"1874_CR77","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1021\/acssynbio.3c00447","volume":"13","author":"M Hoffman","year":"2024","unstructured":"Hoffman M, Cheah KMH, Wittrup KD. A novel gain-of-ignal assay to detect targeted protein degradation. ACS Synth Biol. 2024;13:220\u20139. https:\/\/doi.org\/10.1021\/acssynbio.3c00447.","journal-title":"ACS Synth Biol"},{"key":"1874_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1098\/rsob.170066","volume":"7","author":"LJ Fulcher","year":"2017","unstructured":"Fulcher LJ, Hutchinson LD, Macartney TJ, Turnbull C, Sapkota GP. Targeting endogenous proteins for degradation through the affinity-directed protein missile system. Open Biol. 2017;7:7. https:\/\/doi.org\/10.1098\/rsob.170066.","journal-title":"Open Biol."},{"key":"1874_CR79","unstructured":"Our proprietary platform - T3 Pharmaceuticals. Available at: https:\/\/www.t3pharma.com\/technology. Accessed 01 Jun 2024."},{"key":"1874_CR80","doi-asserted-by":"publisher","first-page":"100034","DOI":"10.1016\/j.engmic.2022.100034","volume":"2","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Han Y. Engineered bacteria as drug delivery vehicles: principles and prospects. Eng Microbiol. 2022;2:100034.","journal-title":"Eng Microbiol"},{"key":"1874_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114363","volume":"187","author":"L Wu","year":"2022","unstructured":"Wu L, Bao F, Li L, Yin X, Hua Z. Bacterially mediated drug delivery and therapeutics: strategies and advancements. Adv Drug Deliv Rev. 2022;187: 114363. https:\/\/doi.org\/10.1016\/j.addr.2022.114363.","journal-title":"Adv Drug Deliv Rev"},{"key":"1874_CR82","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/mt.2013.41","volume":"21","author":"A Le Gou\u00ebllec","year":"2013","unstructured":"Le Gou\u00ebllec A, et al. A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy. Mol Ther. 2013;21:1076\u201386. https:\/\/doi.org\/10.1038\/mt.2013.41.","journal-title":"Mol Ther"},{"key":"1874_CR83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/19490976.2016.1155021","volume":"7","author":"S Felgner","year":"2016","unstructured":"Felgner S, et al. Optimizing Salmonella enterica serovar typhimurium for bacteria-mediated tumor therapy. Gut Microbes. 2016;7:171\u20137. https:\/\/doi.org\/10.1080\/19490976.2016.1155021.","journal-title":"Gut Microbes"},{"key":"1874_CR84","doi-asserted-by":"publisher","unstructured":"Burdette LA, et al. Characterization and Engineering of the Type 3 Secretion System Needle Monomer from\u2009Salmonella\u2009Through the Construction and Screening of a Comprehensive Mutagenesis Library. bioRxiv, 2024.2005.2002.592225. 2024. https:\/\/doi.org\/10.1101\/2024.05.02.592225.","DOI":"10.1101\/2024.05.02.592225"},{"key":"1874_CR85","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1021\/acssynbio.5b00002","volume":"4","author":"AZ Reeves","year":"2015","unstructured":"Reeves AZ, et al. Engineering Escherichia coli into a protein delivery system for mammalian cells. ACS Synth Biol. 2015;4:644\u201354. https:\/\/doi.org\/10.1021\/acssynbio.5b00002.","journal-title":"ACS Synth Biol"},{"key":"1874_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14737","volume":"8","author":"M Song","year":"2017","unstructured":"Song M, et al. Control of type III protein secretion using a minimal genetic system. Nat Commun. 2017;8: 14737. https:\/\/doi.org\/10.1038\/ncomms14737.","journal-title":"Nat Commun"},{"key":"1874_CR87","doi-asserted-by":"publisher","unstructured":"Hansen-Wester I, Chakravortty D, Hensel M. Functional transfer of < i > Salmonella Pathogenicity Island 2 to Salmonella bongori and Escherichia coli. Infect Immun. 2004;72:2879\u201388. https:\/\/doi.org\/10.1128\/iai.72.5.2879-2888.2004.","DOI":"10.1128\/iai.72.5.2879-2888.2004"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-01874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T13:03:37Z","timestamp":1729083817000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-01874-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4705983\/v1","asserted-by":"object"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AK and SK are listed as inventors on issued and pending patents on the monobody technology filed by The University of Chicago (US Patent 9512199 B2 and related pending applications). SK is a co-founder, receives consulting fees and hold equity in Aethon Therapeutics; is a co-founder and holds equity in Revalia Bio; has received research funding from Aethon Therapeutics, Argenx BVBA, Black Diamond Therapeutics, and Puretech Health, all outside of the current work. AD and FL are listed as inventors on an issued patent on the light-controlled T3SS filed by Max Planck Innovation (WO\/2020\/201115). The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"500"}}